Viewing nowCombinationLiragenta Duo Tablet 2.5/500 mg (Linaagliptin Besilate, Metformin Hydrochloride)
Linagliptin Besylate 3.34mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Kyungbo Pharmaceutical Co., Ltd.

MFDS item code 202401042 · Approved 2024.04.30
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used to assist in the control of blood sugar in patients with type 2 diabetes who use linaagliptin and metformin together, complementing dietary management and exercise therapy.
The dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg (linagliptin besylate 3.34mg) and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients who have not previously received drug treatment for diabetes and whose blood glucose cannot be adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should take the same doses of linagliptin and metformin that they were previously taking as the initial dose. 3. Patients whose blood glucose is not adequately controlled with combination therapy with insulin and metformin: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current dose of metformin. When this medicine is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Use with caution in the following patients). Studies evaluating the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine have not been conducted. Any change in the treatment regimen for type 2 diabetes may affect blood glucose control, so caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate [eGFR] 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, discontinue this medicine immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication contains two components and is used to aid in blood sugar control. Firstly, this medication should not be administered to patients with poor kidney function. If kidney function is severely impaired, the medication can accumulate in the body and cause serious side effects. Additionally, this medication can cause a rare but life-threatening metabolic disorder known as lactic acidosis, so it should be avoided in patients with conditions such as severe infections, dehydration, acute myocardial infarction, or heart failure. Patients with an allergy to any components of this medication, patients with type 1 diabetes, and women who are pregnant or breastfeeding should not use this medication. There is a risk of hypoglycemia during use, so blood sugar levels should be carefully monitored, especially when taking it with insulin or drugs from the sulfonylurea class. This medication should also be used cautiously in patients with impaired liver function or severe gastrointestinal disorders, and it should not be administered to patients with acute alcohol intoxication or symptoms of alcohol dependency. Furthermore, this medication can lower vitamin B12 levels, so periodic blood tests to check vitamin B12 status are necessary for long-term use. If iodine contrast agents used in radiological examinations are administered, this medication must be discontinued before and after the test, and kidney function should be checked. Patients about to undergo surgery should stop taking this medication 48 hours prior to the procedure and resume after renal function has normalized. If persistent abdominal pain, severe joint pain, or skin blisters or rashes occur during use, medical consultation should be sought immediately. Women who are pregnant or planning to become pregnant are recommended to control blood sugar through insulin therapy instead of this medication. Older adults may experience decreased kidney function, so regular kidney function tests should be conducted, and dosage should be adjusted as necessary. The safety of this medication has not been established in children and adolescents, so it is not recommended for patients under 10 years of age. Finally, this medication increases the risk of lactic acidosis when taken with alcohol, so it is advisable to avoid drinking.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture. The recommended storage temperature is room temperature between 1 degree and 30 degrees Celsius.
Yellow, biconvex, oval film-coated tablets
30 tablets/bottle, 60 tablets/bottle - 30 tablets/bottle, 30 tablets/bottle, 60 tablets/bottle - 60 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Kyungbo Pharmaceutical Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kyungbo Pharmaceutical Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Kyungbo Pharmaceutical Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
DaiWoong Bio Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Daewoong Bio Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Daewoong Bio Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Mothers Pharmaceutical Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Mothers Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.